A therapeutic vaccine targeting human papillomavirus type 16 (HPV16) induced regression in high-grade precancerous cervical lesions, according to the results from a phase II clinical trial.
"By leveraging the tissue-agnostic capabilities of Virchow V2, Paige PanCancer Detect transforms cancer detection into a broad, scalable AI solution that generalizes the concept of 'cancer' across ...